What We're Reading: Page 105
Industry reads hand-picked by our editors
Apr 13, 2023
-
STAT
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
-
KFF Health News
The Drug Company That Prospered Without Creating Any Drugs
-
Bloomberg
Zealand Pharma Taps Centerview to Explore Partnership Deals
-
The New York Times
Inside the Online Market for Overseas Abortion Pills
Apr 12, 2023
-
NBC News
Cancer drug shortages are creating dire circumstances for some patients
-
Boston Business Journal
More layoffs hit Biogen as drugmaker cuts multiple sclerosis team
-
CNN
Biden administration declares fentanyl laced with xylazine ‘an emerging threat’ in the US
-
Healthcare Dive
Last year was second-best year for healthcare PE deals, Bain finds
Apr 11, 2023
-
CNBC
Health misinformation is lowering U.S. life expectancy, FDA Commissioner Robert Califf says
-
The Washington Post
White House launching $5 billion program to speed coronavirus vaccines
-
The Financial Times
Eli Lilly warns EU will miss out on key drugs under planned change to patent rules
-
Kaiser Health News
For Uninsured People With Cancer, Securing Care Can Be Like Spinning a Roulette Wheel
Apr 10, 2023
-
The Wall Street Journal
The $76 Billion Diet Industry Asks: What to Do About Ozempic?
-
The Washington Post
Assisted-living homes are rejecting Medicaid and evicting seniors
-
Science
Judge dismisses claim that institute defamed David Sabatini in harassment case
Apr 07, 2023
-
Triangle Business Journal
Robert Ingram, pharma leader who led formation of GSK, dies
-
Financial Times
South Korean biotech companies seek to diversify from China as US tensions rise
-
Stat News
Genentech review of Tessier-Lavigne paper finds no fraud
Apr 06, 2023
-
The Wall Street Journal
These Drugs Are So Futuristic That Doctors Need New Training
-
Fierce Pharma
AZ wins royalties case against GSK over PARP inhibitor Zejula
-
MedTech Dive
Grassroots innovation: How a patient-driven device for diabetes won FDA clearance
Apr 05, 2023
-
Financial Times
New Bayer chief says all options on table after investors push for break-up
-
Fierce Pharma
FDA authorizes InflaRx’s anti-inflammation drug for severe COVID
-
The Wall Street Journal
Farallon Capital to Wage Proxy Battle at Biotech Firm
-
Bloomberg
India’s Drug Industry Needs a Major Overhaul
Previous
